( d responds to a certaininteraction par...)Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur,Health

d responds to a certain interaction partner such as hormones, immune mediators or other
substances.
Renin: enzyme that catalyzes the formation of angiotensin I (Ang I) from its precursor angiotensinogen and thus initiates the reninangiotensin
system cascade.
Run-in period: time window during which blood pressure monitoring devices are placed at the participants by specialized staff and first
measurements begin. During this time window blood pressure values can be influenced by the general handling and the contact with the
doctor (so called “white coat effect”).
SBP: systolic blood pressure.
Small molecule drugs: low molecular weight chemical compounds. Many pharmaceutical drugs are small molecules.
Stroke: a sudden interruption in the blood supply of the brain. Most strokes are caused by an abrupt blockage of arteries leading to the
brain; others are caused by bleeding into brain tissue when a blood vessel bursts (see also intracerebral hemorrhage).
Systolic blood pressure: the highest pressure within the arterial blood stream occurring during each heart beat. “Systolic” refers to the
contraction of the heart muscle.
Therapeutic vaccine: a preparation of disease-related molecules (antigens) of foreign or self origin that is capable of activating the
immune system against such antigens with the goal to modulate disease processes.
This foregoing press release may contain forward-looking statements that include words or phrases such as “potentially”, “may”, “would”, “suggest”,
“should”, “might”, “designed”, “intend” or other similar expressions. These forward-looking statements are subject to a variety of significant
uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly fro
'"/>




Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine